Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.
Eli Lilly drops inhaled insulin program.

Diana Nyad cries as she speaks to reporters and fans after arriving back in Key West, Florida August 9, 2011. An asthma attack, a painful shoulder and battering wind and waves forced 61-year-old swimmer Diana Nyad to abandon early on Tuesday her bid to become the first person to swim from Cuba to Florida without a shark cage. REUTERS/Rob O'Neal/Florida Keys News Bureau/Handout The American, who tried and failed the 103-mile swim more than three decades ago when she was 28, gave up after enduring nearly 30 hours of a crossing expected to last 60, exhausted by her body’s limits and the force of the elements. “I thought this was my time. We set out, thinking the conditions were favorable. They were not. The winds were stronger and the waves were bigger than what I’d expected,” she told Reuters after her escort boat Bellisimo brought her to the Key West Yacht Club on Stock Island. Nyad, a veteran long-distance swimmer, had started out strongly, stroking rhythmically through calm seas after she dived off from the Marina Hemingway on the western outskirts of Cuba’s capital Havana at 7:45 p.m. EDT on Sunday. But, she said in an interview with CNN, she suffered an unexpected bout of asthma that left her gasping for oxygen. An “excruciating pain” also developed in her right shoulder and these physical handicaps combined with contrary winds and seas that pushed her floundering off course. “Last night at midnight, I was trembling, the 11 hours of asthma had taken so much from my body ... I just knew that it wasn’t mind over matter any more, I was absolutely spent,” Nyad, wearing a white bathrobe, told CNN at Stock Island. She said that toward the end she was “limping” and “slapping around” in the water and even resorted to breast stroke instead of her usual crawl. Her doctor joined her in the water at one point to try to give her relief with an inhaler. CNN, which had a producer on one of the boats accompanying Nyad, said she was vomiting when she was brought aboard an escort boat at 12:45 a.m. EDT (0445 GMT) on Tuesday. Nyad, who later recovered to breakfast on scrambled eggs on her way to Key West, was disappointed but had no regrets about her motives for attempting the swim. She turns 62 this month. She had said her main aim in attempting the Cuba to Florida swim again, without a shark cage, was to help people her age and older realize they can still achieve many things. “I was the best person I could be ... that’s the message. I dug down, I dug deep ... Whatever you’re doing, do your job well,” Nyad, who has the muscled body and the steely resolve of a marathon swimmer, told CNN. Raised in southern Florida, she first tried the crossing from Cuba in 1978, but failed in the face of winds and heavy waves. The same swim was completed successfully in May 1997 by Australian Susan Maroney, who was 22 at the time. But Maroney used a shark cage. Nyad’s flotilla of escort vessels included specially equipped kayaks transmitting an anti-shark shield in the form of an electronic signal that is annoying to the sleek ocean predators that stalk the waters of the Florida Straits. When she was years younger, Nyad put herself into the record books by swimming around Manhattan in 1975 in less than eight hours and by completing a 102.5 mile swim from Bimini in the Bahamas to Florida in 1979. Despite her having to abandon her bid, her fans tweeted their admiration on Tuesday. “That was Diana’s whole point. Rethink old. Sorry she (had) to abandon but my admiration doesn’t waiver. Go Diana,” said one. Asked whether she would attempt the swim again, Nyad told CNN: “You don’t beat Mother Nature ... I think I’m going to have to go to my grave without swimming from Cuba to Florida.”
Sea defeats body, not spirit, of swimmer, 61.

The researchers have no answer why it is so, but they warn that their findings should not be exploited for sex selection. All fertility clinics that took part in the study comply with Australia’s national guidelines that ban gender selection, the researchers wrote in their findings published on Wednesday in BJOG: An International Journal of Obstetrics and Gynaecology. Led by co-author Jishan Dean from the School of Women’s and Children’s Health at the University of New South Wales, the researchers studied records of 13,165 samples who underwent in-vitro fertilization (IVF). Among women who were given standard IVF, 53 percent had male babies, while 50 percent of women who were given intracytoplasmic sperm injection gave birth to boys. Intracytoplasmic sperm injection is done when sperm is not motile and has to be injected directly into the egg. In standard IVF, sperm and egg are incubated together in a culture medium for about 18 hours and the egg is usually fertilized within that time. More boys seemed to result from embryos that were transferred to the womb 4 days after fertilization (54.1 percent) compared to 2-3 days after fertilization (49.9 percent), the study found. Over the years there has been a big increase in the proportion of IVF births. Philip Steer, editor-in-chief of the BJOG, said in a statement deliberate sex selection in countries like China and India has already led to significant social problems with men being unable to find a wife. “It is important that we don’t allow such imbalances to occur unintentionally, simply because we have neglected to study the factors that influence sex ratio in the increasing proportion of the population who use assisted reproductive technology,” he said.

Fertility treatment may alter gender balance: study.